ImaRx agent completes phase I trials
A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx
A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx claims may be able to significantly enhancegray-scale ultrasound scans in cardiac, blood pool, kidney andliver imaging.
MRX-115 Aerosomes consists of sterile phospholipid-coated microbubbleswith a mean diameter of 2.5 microns. ImaRx plans to use the Aerosomestechnology to develop targeted, site-specific agents for imagingand drug delivery for lymph nodes and diseased tissue.
ImaRx said the phase I trials gave positive results for useof MRX-115 in myocardial perfusion imaging and indicated thatthe agent has a wide safety profile relative to the dose neededfor clinical efficacy. Phase II trials will begin later this year,and ImaRx plans to pursue additional indications for MRX-115 suchas imaging of liver and kidney perfusion.
ImaRx is the developer of SonoRx, an oral ultrasound contrastagent for abdominal imaging under license to Bracco Diagnostics(SCAN 7/27/94 and 3/10/93).
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
